Abbott Announces Positive Results From Groundbreaking Study Of FreeStyle® Libre System For People With Type 1 Diabetes
New Orleans, LA /PRNewswire/ – Abbott (NYSE: ABT) today announced the results of the IMPACT clinical trial, which demonstrated that the FreeStyle® Libre system met its primary endpoint of a reduction in time spent in hypoglycemia (low glucose levels, defined as <70 mg/dL1) for people with type 1 diabetes. People in
Continua a leggere